$ECVT

Ecovyst Inc. (ECVT): Entry into a Material Definitive Agreement

Ecovyst Inc. (ECVT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 d833981dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 Execution Version FOURTH AMENDMENT AGREEMENT This FOURTH AMENDMENT AGREEMENT, dated as of June 30, 2026 (this “ Fourth Amendment ”), is entered into by and among Ecovyst Catalyst Technologies LLC, a Delaware limited liabili

Original reporting
Published Jun 30, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 30, 2026, 8:10 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$ECVT
Neutral
medium confidence
Mentioned
$ECVT
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ECVTNeutralMed
01

Why it matters

The key new information is the creation of a $100M 2026 incremental term facility and its stated use to finance Ecovyst’s acquisition of INEOS Calabrian Holdings Corp. and INEOS Calabrian Corporation Canada, Inc.

02

Market read

This is a credit/funding update tied to an acquisition, which can move expectations for leverage, refinancing risk, and deal execution timing.

03

What to watch

Traders will want the full amendment terms (interest rate, maturity, covenants, fees) and the acquisition purchase price/synergies to judge whether leverage increases are temporary or structural.

Relevance 6/10Novelty 6/10Timing: Filed/posted after-hours on June 30, 2026 (8-K)

Background

The article is an SEC Form 8-K describing a Fourth Amendment to Ecovyst’s existing term-loan credit agreement, including a new $100M incremental term loan tranche.

Company-level read

Ticker impact

$ECVTNeutralMedium confidence
Context

Ecovyst entered a Fourth Amendment to its term-loan credit agreement adding $100M of 2026 incremental term loans tied to an acquisition.

Expected impact

Near-term credit-spread/leverage sensitivity; equity reaction likely muted unless deal economics or terms materially change.

Evidence & confidence

The filing discloses the size and purpose of incremental term loans but does not provide pricing/covenant changes or deal economics in the excerpt.

Market effects

Signals continued M&A financing activity in specialty chemicals/industrial chemicals, potentially relevant for credit conditions among peers with similar capital structures.

Limited direct regional impact; primarily a US-listed issuer credit event.

Deal-funding structure may matter for cross-border chemical supply chains, but no broader macro linkage is provided.

Counterpoint

The incremental facility may be routine and already contemplated; without disclosed covenant/pricing changes, equity impact could be minimal.

Key entities

  • Ecovyst Inc.

    US-listed issuer that entered the Fourth Amendment and requested $100M of 2026 incremental term loans.

  • INEOS Calabrian Holdings Corp.

    Acquisition target referenced as part of the funded transaction.

  • INEOS Calabrian Corporation Canada, Inc.

    Acquisition target referenced as part of the funded transaction.

  • UBS AG

    Administrative agent for the amended credit agreement.

Related articles

$ECVTMedAI 8/10

Ecovyst (ECVT) Q2 2026 Earnings Call Transcript

Ecovyst (ECVT) discussed its Q2 2026 results and strategy on an earnings call. The company closed the Calabrian sulfur dioxide business on June 30, and said Q2 sales rose to $250 million and adjusted EBITDA was $53 million. It reported $13 million adjusted free cash flow for the first half and net debt leverage of 2x after the acquisition. Guidance was revised for higher sulfur pass-through.

$ECVTMedAI 8/10

Ecovyst Q2 Earnings Call Highlights

Ecovyst (NYSE:ECVT) said integration of its Calabrian acquisition is progressing as planned, with no customer disruptions, and expects $3m to $4m in cost and revenue synergies that would lower the acquisition multiple. Q2 sales rose $74m, including $55m sulfur pass-through. It raised 2026 guidance to $1.02b-$1.06b sales and $195m-$207m adjusted EBITDA, citing Calabrian.

$ECVTHighAI 9/10

Ecovyst lifts full-year guidance after second-quarter earnings beat

Ecovyst (NYSE:ECVT) reported Q2 adjusted EPS of $0.21, above the $0.19 consensus, on revenue up 42% to $250 million versus $237.48 million expected. The company raised 2026 guidance: adjusted EBITDA to $195m-$207m and revenue to $1.02b-$1.06b. It also closed an INEOS sulfur dioxide derivatives acquisition in June 2026.

$ECVTHighAI 9/10

Ecovyst Reports Second Quarter 2026 Results and Raises 2026 Outlook

Ecovyst Inc. (NYSE: ECVT) reported Q2 2026 sales of $250.0 million, up 42% year over year, and net income of $10.7 million. Adjusted EBITDA rose 27% to $53.1 million. The company completed the Calabrian sulfur dioxide acquisition on June 30, 2026 and raised full-year 2026 Adjusted EBITDA guidance to $195 million to $207 million.

$ECVTHigh

Ecovyst Inc. (ECVT): Results of Operations and Financial Condition

Ecovyst Inc. (ECVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ecovyst Reports Second Quarter 2026 Results and Raises 2026 Outlook WAYNE, PA, August 5, 2026 -- Ecovyst Inc. (NYSE: ECVT) (“Ecovyst” or the “Company”), a leading provider of regenerated sulfuric acid, virgin sulfuric acid, and sulfur dioxide and related derivatives,